Bayer's Dual Catalyst Week: China Nod for Sunharbo, 58% Risk Cut for Nubeqa — and a Street Still Split Down the Middle

Two pipeline announcements in as many days lifted Bayer shares 3.9% on Monday to a close of EUR 45.65, yet the market's reaction tells only part of the story. The stock move reflects genuine clinical and regulatory progress. What it does not settle is the question now facing investors: how much of that progress is already priced in, and how much depends on the operating numbers due on 03.11.2026.

The more consequential of the two disclosures came on Sunday, when Bayer reported interim results from the Phase III DASL-HiCaP trial. In the analysis, Nubeqa (darolutamide) — given alongside androgen deprivation therapy and radiotherapy — cut the risk of metastases or death by 58% versus placebo, which was administered with the same ADT and radiotherapy backbone. The median follow-up stood at 3.8 years, and the combined endpoint covered both metastasis and death.

Bayer also disclosed absolute figures for a fixed observation point. Four-year metastasis-free survival reached 95% in the Nubeqa arm against 88% in the comparator group — a detail that gives the relative risk reduction a concrete frame rather than leaving it as a headline percentage. The finding applies strictly to the studied regimen and population; extrapolating beyond that setting would go further than the data allow.

Monday brought a different kind of milestone. China's regulator approved Asundexian under the brand name Sunharbo for reducing stroke risk in adults following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Bayer described the compound as the world's first approved FXIa inhibitor — a concrete regulatory clearance, not a pending decision whose outcome remains unknown.

Should investors sell immediately? Or is it worth buying Bayer?

The distinction matters for how the two events should be read. An approval establishes a legal and regulatory basis for commercialization; a positive interim analysis demonstrates medical benefit within the trial's parameters. Neither is the same as a realized contribution to revenue, and the reporting period investors are waiting on predates these announcements. The third-quarter figures, scheduled for 03.11.2026, should not be mistaken for the first financial proof of either advance.

Where the two announcements converge is in their effect on the investment debate. The question is no longer whether Chinese approval would arrive, nor whether the prostate data would hold up. It is whether the regulatory and clinical wins can be converted into an economically convincing trajectory. A favorable scenario has the next set of results reinforcing operating confidence, allowing the product news to be treated as incremental upside rather than the sole pillar of the valuation.

The analyst community has not converged on that view. JPMorgan reaffirmed an "Overweight" rating and a EUR 61 price target on Monday, with Richard Vosser taking a positive read on the DASL-HiCaP interim data. Jefferies, by contrast, kept Bayer at "Hold" with a EUR 46 target following the same darolutamide results. Identical study news, two very different conclusions about what the equity is worth.

That split is the useful caveat here. A constructive interpretation of the science does not by itself answer the pricing question. If the operating performance disappoints or expectations prove too ambitious, the market may assign less weight to pipeline news — without invalidating the regulatory or clinical achievement itself. The upside case rests not on stretching the data but on pairing robust trial evidence with a business trajectory that confirms it.

For now, the two strands — commercial execution and medical progress — remain separate tracks. They could reinforce each other if the coming results support the operating story. Should that foundation prove weaker, attention will shift toward execution, and the approval and study data, while still relevant, would carry less weight as standalone arguments. The more durable thesis is the one in which both point the same way.

Ad

Bayer Stock: New Analysis - 27 October

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...